Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
2
self-reported 2–10 band
Founded
2023
3 years
Legal entities
None matched
Office countries
1
1 address
Funding rounds
None on record
Company type
Privately Held
self-reported
Description
NexCalibur Therapeutics is a pre-clinical stage biotechnology company that focuses on developing an innovative platform to design and produce personalised therapies and preventative vaccines for solid tumor cancers.
Our personalised therapies are designed based on neoantigens, which are unique peptides from cancer cells that can trigger strong and specific immune responses against tumors while avoiding damage to healthy tissues.
Our NexNeo platform uses a unique combination of artificial intelligence (AI) and engineered antigen-presenting cells to speed up the identification and validation of neoantigens, producing a cocktail of multiple neoantigens tailored for each patient.
NexNeo platform is currently on a hybrid phase I/II clinical trial focusing on metastatic colorectal cancer patients.
Our NexNeo platform can also be used to design preventive cancer vaccine for healthy individuals with high risk of developing cancer (ie. family history or early signs of malignancy).
We conducted a large-scale screening for “public neoantigens” (ie. neoantigens commonly found in multiple individuals), which together could be formulated into “off-the-shelf” preventive vaccines.
This approach of early intervention could potentially save lives at a much lower cost, especially in high-risk individuals.
Specialties
All 12 specialties
- Immunotherapies
- Oncology
- Neoantigen
- Artificial Intelligence
- Cancer Preventive Vaccines
- Cancer Treatment Vaccines
- Machine Learning
- Preclinical Models
- Big Data
- Healthcare Transformation
- Biotechnology
- Neoantigen Vaccines
Related specialties
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | SG |
All codes: SG
Addresses
- SG20a Tanjong Pagar Road; Outram, Central Singapore Community Development Council 088443Primary
Grid intelligence Members
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
1 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
The people relation is never requested, so there is nothing here to unlock.
FAQ
How many people work at NexCalibur Therapeutics?
2 counted staff profiles at January 2026, inside the self-reported 2–10 band.
Where does NexCalibur Therapeutics have offices?
One address on record, Singapore only. Primary: 20a Tanjong Pagar Road, Outram, Central Singapore Community Development Council 088443.
Has NexCalibur Therapeutics raised funding?
None linked to this brand.
What does NexCalibur Therapeutics list as its specialties?
12 tags on the brand's own list, among them machine learning, artificial intelligence and big data.
Which companies are listed alongside NexCalibur Therapeutics?
5 profiles list NexCalibur Therapeutics as a peer — 62nd percentile in Biotechnology Research. It lists ten peers of its own. Singzyme and Builders' Base list it back.